If they want to launch they can't do that anymore. The time is now and I am quite sure they know it. Pushing MANF forward is important and I agree MANF is tr major value driver in the out years. Dave is right about Lympro. AMBS is about to be a revenue generating company. The diagnostic market for Alzheimer's is massive beyond research and more than good enough in the clinical trial market. The promise of revenue will have a significant effect on share price before the first dollar is collected.